Actively Recruiting
Biomarkers and Imaging to Identify High-Grade Dysplasia and Invasive Carcinoma in Pancreatic Intraductal Papillary Mucinous Neoplasms
Led by IRCCS San Raffaele · Updated on 2024-11-26
586
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating biomarkers and imaging methods to better identify high-grade dysplasia and invasive carcinoma in patients with intraductal papillary mucinous neoplasms IPMN of the pancreas. This study aims to improve patient selection to reduce overtreatment and distinguish benign IPMNs from those with higher cancer risk by examining endocrine, metabolic, and inflammatory profiles. The study has three main goals to validate updated international and European guidelines retrospectively, to identify biomarkers in a prospective patient group, and to validate these biomarkers in a new surgical cohort. The study includes three cohorts a retrospective group of 350 patients with resected IPMN analyzed to validate guideline accuracy a prospective observational cohort of 186 patients 145 undergoing surgery to identify biological and imaging biomarkers using MRI and endoscopic ultrasound EUS and a third prospective cohort of 50 patients to validate the identified biomarkers. Imaging assessments focus on features such as main pancreatic duct involvement and surrounding tissue characteristics. Patients undergo standard pre-operative MRI and EUS exams within a three-month window. Participants are involved through retrospective data review or prospective enrollment with informed consent. Assessments include clinical, radiological, and biological evaluations, with follow-up to measure endocrine, metabolic, and inflammatory profiles and imaging biomarkers. Outcomes focus on guideline accuracy, biomarker effectiveness in predicting pathology, and comparison of MRI versus EUS accuracy. The study is observational and does not involve investigational treatments, with participation lasting up to 12 months depending on cohort and follow-up schedule.
CONDITIONS
Brief Title
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
Research Team
S
Stefano Crippa, MD
P
Paolo Camisa, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here